Background: Osteoarthritis is the most common musculoskeletal disease worldwide. Spinal osteoarthritis (OA) is a frequent cause of back pain and disability in patients over 60. The frequency of radiographically-evident dorsal and lumbar OA in Latin America is unknown Objectives: To determine the prevalence of dorsal and lumbar vertebral OA in a database-driven random sample of women 50 years of age and older from the Latin-American Vertebral Osteoporosis Study (LAVOS) in 5 LA countries (México, Brazil, Argentina, Colombia and Puerto Rico) Methods: Lumbar and Dorsal X-rays were performed per a standardized protocol and analyzed independently by two trained radiologists and a general practitioner using the Lane score to establish diagnosis and degree of vertebral OA severity. Inter and intra observer agreement was determined to be k>0.6.
AB0816 COMPREHENSIVE ANALYSIS OF A NEW CHEMICAL COMPOUND FOR THE TREATMENT OF OSTEOARTHRITIS BY A PROTEOMIC APPROACH IN HUMAN CHONDROCYTES
Background: Selective cyclooxigenase (COX)-2 inhibitors were developed to prevent NSAIDs gastro-intestinal adverse effects. VA692, a new hydroxyetyl selective COX-2 inhibitor, showed anti-inflammatory, anti-nociceptive and chondroprotective properties. Proteomics is being applied for the study of drug mode of action, toxicity and to identify new drugs targets. Objectives: The aim of this study was to analyze the anti-inflammatory effect of VA692, in comparison with celecoxib. By iTRAQ methodology, we quantitatively analyzed the different expressed profiles in T/C-28a2 cell line treated with the studied drugs in presence of IL-1β. Methods: Human T/C-28a2 chondrocytes cell line were generated by Goldring group. Human articular cartilage was obtained from femoral heads of five OA patients. Cells were incubated with VA692 and celecoxib (1, 0.5 and 0.2μM) in presence of Interleukin (IL)-1β (5ng/ml) for 48h. The expression of inflammatory cytokines and anti-oxidant enzymes was evaluated by quantitative qRT-PCR, PGE 2 release by ELISA, and apoptosis and ROS production by flow cytometry. T/C-28a2 cell line was also processed to carry out western blot tests and finally employed for the iTRAQ analysis. Statistical analysis was performed by ANOVA and Bonferroni multiple comparison tests. Results: IL-1β-stimulated chondrocytes showed a significant increase (p<0.001) of COX-2, IL-1β, IL-6, IL-8, superoxide dismutase (SOD)-2 and catalase (CAT) gene expression, as well as of PGE2 levels. The tested drugs significantly counteracted the effect of IL-1β, with a better modulation by VA692 1μM in T/C-28a2 cell line (p<0.01 for COX-2, IL-1β, IL-8, CAT; p<0.001 for IL-6, SOD-2). Regarding apoptosis and ROS production, the new drug was able to significantly reduce (p<0.05) their increase induced by IL-1β (p<0.05). Proteomic analysis led to identification of 797 proteins in T/C28a2 cell line, 123 of which were significantly modulated by VA692 in presence of IL-1β (p<0.001), and 34 by IL-1β alone (p<0.05). 22 proteins were commonly modulated in both groups, thus indicating that 101 proteins were regulated by VA692 in a specific manner. Among the proteins down-regulated by VA692, some with structural function were detected, responsible for cytoskeleton riorganization, as well as chaperones (heat shock proteins) and glycolitic enzymes. Proteins involved in calcium metabolism and in ribosome biogenesis resulted up-regulated instead, as well as SOD-2 as confirmed by western blot analysis. Conclusions: Our data demonstrated the anti-inflammatory effect of VA692, suggesting also its anti-apoptotic and anti-oxidant role. The proteomic profile showed that VA692 induced not only an anti-inflammatory effect in chondrocytes but, interestingly, this compound also seemed to regulate their anabolic response. Background: EULAR guidelines for osteoarthritis (OA) endorse high quality care and support to self-manage with core recommended treatments such as exercise, weight loss and the provision of written information and education. An EU-funded project, Joint Implementation of Guidelines for oSteoArthritis in Western Europe (JIGSAW-E) 1 , aims to improve the management of OA across five European countries (UK, Netherlands, Norway, Denmark, Portugal) by implementing an intervention to enhance the OA consultation. 
